维生素K | 83-70-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 维生素K
• 英文名称: vitamin K5
• 英文别名: 4-amino-2-methylnaphthalen-1-ol
• CAS: 83-70-5
• 化学式: C₁₁H₁₁NO
• mdl: MFCD00053481
• 分子量: 173.214
• InChiKey: UGQFCTZXVAPVCS-UHFFFAOYSA-N

物化性质

• 沸点：
  303.86°C (rough estimate)
• 密度：
  1.0898 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2922299090
• 储存条件：
  库房应保持通风、低温和干燥的环境。

制备方法与用途

类别：有毒物品

毒性分级：高毒

急性毒性：腹腔-小鼠LD50: 250 毫克/公斤

可燃性危险特性：可燃；燃烧时产生有毒氮氧化物烟雾

储运特性：库房需通风、低温和干燥保存

灭火剂：干粉、泡沫、砂土、二氧化碳及雾状水

反应信息

• 作为反应物：
  描述：

  维生素K 在 caesium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 N-(3-methyl-4-((3-(2-(methylamino)-4-pyrimidinyl)-2-pyridinyl)oxy)-1-naphthalenyl)-1H-benzimidazol-2-amine
  参考文献：
  名称：

  Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase

  摘要：

  Selective small molecule inhibitors of Tie-2 kinase are important tools for the validation of Tie-2 signaling in pathological angiogenesis. Reported herein is the optimization of a nonselective scaffold into a potent and highly selective inhibitor of Tie-2 kinase.

  DOI：

  10.1016/j.bmcl.2008.11.056
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 、 tin(ll) chloride 作用下， 生成 维生素K
  参考文献：
  名称：

  Veldstra; Wiardi, Recueil des Travaux Chimiques des Pays-Bas, 1943, vol. 62, p. 75,84

  摘要：

  DOI：

文献信息

• Fluorinated compounds
  申请人：Zhang Yuehua

  公开号：US06864386B1

  公开（公告）日：2005-03-08

  Fluorinated compounds and emulsions including the compounds. The compositions are useful as oxygen carriers and surfactants. In one embodiment, the fluorinated compound is pH sensitive. In one embodiment, the fluorinated compound is a vitamin E derivative. In one embodiment, the fluorinated compound is a vitamin K derivative.

  氟化合物和包括这些化合物的乳化液。这些组合物可用作氧载体和表面活性剂。在一个实施例中，氟化合物是pH敏感的。在一个实施例中，氟化合物是维生素E衍生物。在一个实施例中，氟化合物是维生素K衍生物。
• Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors
  作者：Ute F. Röhrig、Loay Awad、Aurélien Grosdidier、Pierre Larrieu、Vincent Stroobant、Didier Colau、Vincenzo Cerundolo、Andrew J. G. Simpson、Pierre Vogel、Benoît J. Van den Eynde、Vincent Zoete、Olivier Michielin

  DOI：10.1021/jm9014718

  日期：2010.2.11

  design new inhibitors of this enzyme. First, we investigated the modes of binding of all known IDO inhibitors. On the basis of the observed docked conformations, we developed a pharmacophore model, which was then used to devise new compounds to be tested for IDO inhibition. We also used a fragment-based approach to design and to optimize small organic molecule inhibitors. Both approaches yielded several

  吲哚胺2,3-双加氧酶（IDO）是治疗癌症等涉及病理性免疫逃逸的疾病的重要治疗靶点。我们使用进化对接算法 EADock 来设计该酶的新抑制剂。首先，我们研究了所有已知 IDO 抑制剂的结合模式。根据观察到的对接构象，我们开发了药效团模型，然后用该模型设计新化合物以测试 IDO 抑制作用。我们还使用基于片段的方法来设计和优化小有机分子抑制剂。这两种方法都产生了几种新的低分子量抑制剂支架，其中最活跃的是酶测定中的纳摩尔效力。细胞测定证实了四种不同支架的潜在生物学相关性。
• [EN] IDO INHIBITORS AND THERAPEUTIC USES THEREOF<br/>[FR] INHIBITEURS D'IDO ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：LUDWIG INST FOR CANCER RES LTD

  公开号：WO2011045341A1

  公开（公告）日：2011-04-21

  Compounds of formula (I) in which R1, R2 and R3, which may be the same or different, represent alkyl C1-6, cycloalkyl C3 - 7, aryl or NHR4, wherein R4 may represent any of the values that any of R1, R2 or R3 may represent; additionally, R3 may represent hydrogen, and pharmaceutically acceptable salts thereof, and their therapeutic use, eg in the treatment of cancer.

  化学式（I）中的化合物，其中R1、R2和R3，可以相同也可以不同，代表烷基C1-6、环烷基C3-7、芳基或NHR4，其中R4可以代表R1、R2或R3中的任何一个值；此外，R3可以代表氢，并且其药用盐，以及它们在治疗癌症等方面的治疗用途。
• Inhibitors against the activation of ap-1 and nfat
  申请人：Muto Susumu

  公开号：US20060100257A1

  公开（公告）日：2006-05-11

  A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物，抑制AP-1的激活，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物中所选的一种，其中X代表连接基，其主链中的原子数为2至5（该连接基可以被取代），A代表氢原子或乙酰基，E代表芳基或取代的杂芳基，环Z代表芳烃，除了由式—O-A所表示的基团外，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义，或者是一个杂芳烃，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义。
• Medicament for treatment of diabetes
  申请人：Muto Susumu

  公开号：US20060111409A1

  公开（公告）日：2006-05-25

  A medicament for preventive and/or therapeutic treatment of diabetes or complications of diabetes which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O— A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种用于预防和/或治疗糖尿病或糖尿病并发症的药物，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物之一： 其中，X代表主链中原子数为2到5的连接基（该连接基可以被取代），A代表氢原子或乙酰基，E代表可以被取代的芳基或杂环芳基，环Z代表可以具有一个或多个取代基的芳基，除了由公式—O—A所表示的基团外，该芳基可以具有公式—X-E所表示的基团，其中每个X和E的含义与上述定义相同，或者可以具有一个或多个取代基的杂环芳基，除了由公式—O—A所表示的基团外，该杂环芳基可以具有公式—X-E所表示的基团，其中每个X和E的含义与上述定义相同。